ASCO 2016: Current treatment approaches for advanced prostate cancer

Bookmark and Share
Published: 7 Jun 2016
Views: 3028
Prof Przemyslaw Twardowski and Prof Gordon McVie

Prof Twardowski (City of Hope Hospital, Duarte, USA) shares this views on the current treatment approaches for advanced prostate cancer and key highlights from ASCO 2016.

Discussion focuses on the need for precision medicine and highlights a university of Chicago phase II consortium trial – A ramdomised ETS gene fusion stratified trial of abiraterone prednisone /- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer and shares some encouraging data for patients with a DNA repair gene mutation.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).